Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: Nov 4, 2025
Completed enrollment in soquelitinib atopic dermatitis Phase 1 trial extension cohort 4 (200 mg BID dose with 8-week treatment period) with data announcement anticipated in January
Read more at globenewswire.com
